Solid Biosciences Inc. (SLDB) › Cash & EquivalentsSolid Biosciences Inc. (SLDB) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2016: $7.68M2017: $52.08M2018: $86.37M2019: $76.04M2020: $154.74M2021: $119.14M2022: $155.38M2023: $74.02M2024: $80.23M2025: $59.90M$59.90M2016Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$59.90M-25.3%2024$80.23M+8.4%2023$74.02M-52.4%2022$155.38M+30.4%2021$119.14M-23.0%2020$154.74M+103.5%2019$76.04M-12.0%2018$86.37M+65.8%2017$52.08M+578.3%2016$7.68M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share